Engineering Impact in Drug Discovery and Development

Julie Fogarty, PhD, TX A ‘13

Research Scientist

Formulation and Process Development

Gilead Sciences, Inc

Foster City, CA

The talk: During her talk, Julie will discuss the role the rich history of drug development at Gilead and how formulation and process development has been critical to the progress that has been made in advancing many of Gilead’s therapeutics. Julie will also detail the impact a chemical engineer can have on the drug discovery and development process from early stage pre-clinical studies all the way to a commercial product. She will wrap up with some thoughts on the future of drug discovery and development.

Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. Together we deliver life-saving therapies to patients in need, changing the world and helping millions of people live healthier, more fulfilling lives. Our scientific focus has resulted in marketed products that are benefiting hundreds of thousands of people, a pipeline of late-stage drug candidates, and unmatched patient access programs to ensure medications are available to those who could otherwise not afford them. Our ongoing mission is to address unmet medical needs and improve life by advancing the care of patients with life-threatening diseases.

The speaker: Julie Fogarty received her BS in Chemical Engineering from the University of Texas at Austin in 2013. Immediately following her undergraduate studies, Julie pursued a PhD in Chemical Engineering at Stanford, receiving her MS in Chemical Engineering in 2015 and her PhD in Chemical Engineering in 2019. Since graduating from Stanford University, Julie has worked as a Research Scientist in Formulation and Process Development at Gilead Sciences.

Register here:

https://tbp-org.zoom.us/meeting/register/tZ0tcumoqDorHtPQxnRTt5AJWBMhG1leBcbm